231 results
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially … for and ability to access sufficient additional financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks related
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
with BlackRock EMEA Venture and Growth Lending (previously Kreos Capital) was originally announced in September 2022.
“We are very pleased to be able to access … of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors … , future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
preparation of financial statements in conformity with IFRS and to maintain asset accountability, (iii) access to assets is permitted only in accordance … and, at the present time, is able to afford a complete loss of such investment.
(e) Access to Information. Such Purchaser acknowledges that it has had the opportunity
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
approvals for our therapeutic candidates and the timing of other regulatory filings and approvals;
whether access to APHEXDA is achieved … the intellectual property rights of others;
estimates of our expenses, future revenues, capital requirements and our needs for and ability to access sufficient
20-F/A
c27uhx1zv
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
x81 uevlqtxb95
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
dj6 zds26cmk
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
47th2xx6 7z
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
dlo j3cqrd8jnaxlqdb1
16 Feb 24
Current report (foreign)
7:07am
F-3
euqbia jm7k6ur9r3aza
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
gyqi1
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
nglqp9vt
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
bmw1qddx
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
o3srh7g378q2emvad65
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
1006s3vxqctay
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
6ti9lmcanr6c4i1y5
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
e1dcmv
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am